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a b s t r a c t 
Background: There is little information on the prevalence of recreational drug use among UK heterosexual men 
and women, in particular on use of drugs associated with ‘chemsex’ within gay communities. The aim of this study 
was to examine among HIV-negative and HIV-positive heterosexual men and women in England: (i) the prevalence 
of recreational drug use (including use of drugs associated with chemsex), (ii) socio-economic/lifestyle correlates 
of drug use, and (iii) the association of drug use with sexual behavior measures and mental health symptoms. 
Methods: Data are from the AURAH study of HIV-negative individuals attending sexual health clinics across Eng- 
land (2013–2014) and the ASTRA study of HIV-positive individuals attending HIV outpatient clinics in England 
(2011–2012). Prevalence of recreational drug use (past three months) and associations are presented separately 
among the four sample groups: HIV-negative ( N = 470) and HIV-positive ( N = 373) heterosexual men and HIV- 
negative ( N = 676) and HIV-positive ( N = 637) women. 
Results: The age standardized prevalence of any drug use was 22.9%, 17.1%, 15.3%, and 7.1% in the four 
sample groups respectively. In all groups, cannabis was the drug most commonly used (range from 4.7% to 17.9%) 
followed by cocaine (1.6% to 8.5%). The prevalence of use of drugs associated with chemsex was very low among 
HIV-negative participants (1.0% heterosexual men, 0.2% women) and zero among HIV-positive men and women. 
In age-adjusted analysis, factors linked to drug use overall and/or to cannabis and cocaine use specifically in the 
four sample groups included Black/mixed Caribbean and white (vs. Black/mixed African) ethnicity, lower level 
of education , cigarette smoking, and higher risk alcohol consumption. Associations of recreational drug use with 
measures of condomless sex, depression, and anxiety were observed in the four groups, but were particularly 
strong/apparent among women. 
Conclusion: Providers need to be aware of cannabis and cocaine use and its potential link with sexual risk 
behavior and symptoms of depression and anxiety among heterosexual men and women attending sexual health 











In the Crime Survey for England and Wales (2017/2018), a
opulation-based study, the prevalence of any recreational drug use in∗ Corresponding author. 
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mong men and women aged 16 to 24 years ( ONSFlatley, 2018 ). The
se of recreational drugs has been linked to depressive symptoms, sex-
al risk behavior and increased risk of HIV infection ( Scott et al., 2007 ).
n a recent meta-analysis of seven studies (one in the UK), cannabis
se during adolescence was associated with depression in young adult-
ood (pooled OR 1.37 [95% CI: 1.16, 1.62]) ( Gobbi et al., 2019 ). Inticle under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 






















































































































he British National Survey of Sexual Attitudes and Lifestyles (Natsal,
010–2012), past year use of illicit drugs was strongly associated with
eporting two or more condomless sex (CLS) partners in the past year
mong both men (OR 5.50 [95% CI: 3.61, 8.39]) and women (OR 5.24
95% CI: 3.07, 8.94]), adjusting for age ( Paquette et al., 2017 ), but in-
ormation on type of drug used was not available. There is a need for
rug-specific prevalence estimates and information on associations with
exual behavior and mental health measures among heterosexual men
nd women in the UK. This includes people living with HIV, for whom
here are very limited data. 
There is also a need to investigate whether the use of drugs associ-
ted with chemsex, which have been trending within gay communities
ver the past decade, have also gained popularity among heterosexual
en and women in the UK. The phenomenon of chemsex has been docu-
ented since 2013 ( Stuart, 2019 ). It involves the use of one or more psy-
hoactive substances (mephedrone, gamma-hydroxybutyrate/gamma-
utyrolactone [GHB/GBL] and/or methamphetamine) during or imme-
iately before sex ( Bourne, Reid, Hickson, Torres Rueda, & Weather-
urn, 2014 ). These drugs tend to impact on sexual arousal, euphoria,
nd disinhibition to a greater extent than other commonly used recre-
tional drugs, with implications for increased risk of STI/HIV trans-
ission. Qualitative work suggests that chemsex is practiced in order
o facilitate different/new sexual practices and prolong sexual episodes
 Bourne, Reid, Hickson, Torres Rueda, & Weatherburn, 2014 ). 
A growing number of survey studies have examined the preva-
ence of chemsex or use of drugs associated with chemsex among
IV-negative and HIV-positive gay, bisexual and other men who have
ex with men (GBMSM) in Europe ( Daskalopoulou et al., 2014 , 2017 ;
ruckler, van Rooijen & de Vries, 2018 ; Glynn et al., 2018 ; Hegazi et al.,
017 ; Ottaway, Finnerty, Buckingham & Richardson, 2017 ; Sewell et al.,
018 , 2017 ; Tomkins et al., 2018 ). Use of drugs associated with chem-
ex was reported by over a fifth of 1484 HIV-negative GBMSM attend-
ng sexual health clinics in the AURAH study in England (2013–2014),
nd was very strongly associated with group sex and CLS ( Sewell et al.,
017 ). Similar findings have been observed in other recent studies in
urope. There is also some evidence that the prevalence of drug use
ssociated with chemsex is increasing among GBMSM ( Hampel et al.,
019 ; Sewell et al., 2018 ). 
The extent to which the types of drugs associated with chemsex
ithin gay communities are used among heterosexual men and women
s uncertain. It remains unclear whether harm reduction messaging sur-
ounding use of drugs associated with chemsex should also target het-
rosexuals. This is a particularly pertinent issue given the recent rise in
onorrhoea, syphilis and chlamydia diagnoses among heterosexual men
nd women in England ( Mitchell et al., 2020 ). It is acknowledged how-
ver, that the phenomenon of chemsex emerged as a means by which
o facilitate enjoyment of gay sexuality against the backdrop of a het-
ronormative and homophobic social environment ( Stuart, 2019 ). In
any respects the practice of chemsex may be unique to gay commu-
ities. Among GBMSM, investigating the use of drugs associated with
hemsex is thought to be a good reflection of the practice of chemsex it-
elf ( Stuart, 2013 ). However, this may not be the case among heterosex-
al populations, for whom these drugs may be used outside of a sexual
etting. 
This analysis uses data from two cross-sectional studies in Eng-
and and investigates among HIV-negative and HIV-positive heterosex-
al men and HIV-negative and HIV-positive women separately: (i) the
revalence of recreational drug use (any, individual drugs, multiple
rugs, and use of drugs associated with chemsex within gay commu-
ities), (ii) the association of socio-economic and lifestyle factors with
ecreational drug use (any and the two most common drugs), (iii) the
elationship of recreational drug use (any and the two most common
rugs) with symptoms ofdepression and anxiety, and (iv) the relation-
hip of recreational drug use (any and the two most common drugs)
ith sexual behavior/attitudes. (
2 ethods 
In this paper, data were analysed from two separate cross-sectional
uestionnaire studies in England. The Attitudes to and Understanding
f Risk of Acquisition of HIV (AURAH) study recruited HIV-negative
r unknown HIV status men and women (hereafter referred to as HIV-
egative) from 20 sexual health clinics in England between June 2013
nd November 2014. Individuals aged 18 years or older without diag-
osed HIV were eligible for inclusion. Methodological details have been
ublished elsewhere ( Sewell et al., 2016 ). The Antiretrovirals Sexual
ransmission Risk and Attitudes (ASTRA) study recruited HIV-positive
en and women aged 18 years or older from eight HIV outpatient clinics
n England between February 2011 and December 2012. Methodologi-
al details have been published elsewhere ( Speakman et al., 2013 ). All
easures used in this analysis were obtained from the study question-
aire, which was self-administered in both studies. 
opulation groups under investigation 
In AURAH, men who reported being heterosexual/straight and did
ot report anal sex with a man in the past three months, nor disclose
o their family, friends or workmates as being gay, bisexual and/or
ttracted to men, were included in the heterosexual men category
 N = 470). All women were analysed together ( N = 676) regardless of
heir sexual orientation/sexual behavior due primarily to the very small
umber of gay/lesbian women in this study ( N = 3). In ASTRA, men
ho reported being heterosexual/straight and did not report anal sex
ith a man in the past three months were included in the heterosexual
en category ( N = 373). The question on disclosure of sexual orien-
ation to family, friends and workmates was not asked in the ASTRA
uestionnaire. Again, all women were analysed together ( N = 637). 
ecreational drug use 
The questions on drug use were identical in AURAH and ASTRA. Par-
icipants were asked to report whether they had used recreational drugs
n the past three months and, if so, to select which drug or drugs from
he following list of 18 options: acid/LSD/magic mushrooms; anabolic
teroids; cannabis (marijuana, grass); cocaine (coke); crack; codeine;
rystal meth (methamphetamine); Ecstasy (E, MDMA); GHB (liquid ec-
tasy, GBL); heroin, ketamine (K); khat (chat); mephedrone; morphine;
pium; poppers (amyl nitrate, nitrites); speed (amphetamine); viagra
erectile dysfunction drugs) (and other). Other drugs specified were
oded to the above categories where appropriate. Participants were also
sked whether in the past three months they had injected recreational
rugs (e.g. heroin, crystal meth). 
Three composite measures of recreational drug use were defined: 
i) Any recreational drug use: use of at least one of the 18 drugs listed
above in the past three months. 
ii) Poly drug use: use of at least three different recreational drugs (from
the above list of 18) in the past three months. Information was not
collected on whether these drugs were taken concurrently. 
ii) Use of drugs associated with chemsex within gay communities: use
of one or more of mephedrone, methamphetamine or GHB/GBL in
the past three months. It should be noted that the questionnaires did
not ask about drug use during sex specifically. 
exual behavior and attitudes 
From the questions in AURAH and ASTRA, four comparable mea-
ures of sexual behavior and attitudes were derived: 
i) CLS with a non-regular partner in the past three months, defined
as report of more than one CLS partner or one CLS partner who was
not a long-term partner. 
ii) CLS with two or more partners in the past three months. 

























































































































t  ii) Self-efficacy for sexual safety: ‘I feel confident that, if I want to, I
can make sure a condom is used during sex with any partner, in any
situation.’ If a participant did not strongly agree with this statement
(i.e. responded with tend to agree, tend to disagree, strongly dis-
agree, undecided/no opinion/not relevant to me, or had a missing
response) this was considered to indicate low self-efficacy for sexual
safety. This categorisation was chosen due to the high proportion of
participants who agreed with this statement, therefore, it was be-
lieved appropriate to separate participants who specified ‘tend to
agree’ from those who specified ‘strongly agree’. 
v) Transactional sex for money or drugs in the past three months. In-
formation on the gender of the client was not obtained. 
ymptoms of depression and anxiety 
In both studies, the Patient Health Questionnaire (PHQ-9) and Gen-
ralized Anxiety Disorder Assessment (GAD-7) were used to collect in-
ormation on depressive symptoms and anxiety symptoms respectively
 Kroenke, Spitzer & Williams, 2001 ; Kroenke, Spitzer, Williams, Mona-
an & Lowe, 2007 ). A total score of 10 or greater on PHQ-9 was consid-
red to indicate clinically significant depressive symptoms, according
o the standard definition. Similarly, the standard definition of a total
core of ≥ 10 on the GAD-7 was used to define clinically significant anx-
ety symptoms. 
tatistical analysis 
The prevalence of individual drug use and composite measures were
resented for (a) HIV-negative participants in the AURAH study and
b) HIV-positive participants in the ASTRA study, separately for hetero-
exual men, women and GBMSM (the latter has already been reported
 Daskalopoulou et al., 2014 ) and is shown here for comparison). In or-
er to facilitate comparison of drug use prevalence in AURAH and AS-
RA, estimates are presented standardized for age. The age-standardized
revalence is the weighted average of drug use prevalence in each age
roup ( < 35, 35–44, 45 + ), using the age distribution in AURAH and AS-
RA combined to obtain the weights (38.6% < 35; 27.8% 35–44; 33.6%
5 + ). 
The remainder of the paper focuses on heterosexual individuals only,
ith all analyses conducted in the four sample groups separately: HIV-
egative and HIV-positive heterosexual men, and HIV-negative and HIV-
ositive women. 
Associations of socio-economic and lifestyle factors with any drug
se and the two most common drugs taken were assessed among the
our sample groups. Given the low prevalence of poly drug use and use of
rugs associated with chemsex in our samples, these measures were not
nvestigated further. For univariable analysis, 𝜒2 tests, 𝜒2 tests for trend
nd (when expected numbers were small) Fisher’s exact tests were used
o compare drug use between subgroups. Modified Poisson regression
ith a robust variance estimator was used to produce prevalence ratios
PRs) adjusted for age (as a continuous variable) ( Zou, 2004 ). 
Associations of any drug use and the two most common drugs taken
ith symptoms of depression and anxiety, and with measures of CLS and
elf-efficacy for sexual safety were assessed. Using modified Poisson re-
ression the following key socio-demographic factors were adjusted for:
ge (continuous variable), ethnicity (Black/mixed African or other eth-
icity), university education (yes or no/missing), ongoing relationship
yes or no/missing), and London clinic site (London or outside London).
or some outcome measures, prevalence was low and only unadjusted
ssociations are presented. For HIV-positive sample groups this was the
ase for all measures of CLS, therefore findings related to this group are
resented in the text only. 
The proportion of missing values was < 5% for all variables used in
nalyses. Missing values were incorporated into specific categories for
he measures of drug use, depression and anxiety symptoms, CLS, uni-
ersity level of education, being employed, ongoing relationship, cur-3 ent smoking and higher risk drinking (missing was taken to mean the
bsence of the factor). For all other variables, participants with missing
ata were excluded from analysis. A sensitivity analysis was undertaken
xcluding missing values when defining all variables. The findings were
ery similar to the main analysis (data not shown). Analyses were per-
ormed by STATA statistical software ( StataCorp, 2009 ) and were re-
orted according to the STROBE guidelines ( STROBE, 2009 ). 
esults 
In total, 2630 individuals participated in the AURAH study (response
ate was 60% of eligible patients approached), of whom 470 were het-
rosexual men and 676 were women. On the self-reported question-
aire, all participants reported that they had not been diagnosed with
IV. Overall, 346 heterosexual men and 446 women had an HIV test
n the day of the AURAH questionnaire. Four heterosexual men and
ne woman tested HIV-positive. These five individuals were retained in
he sample for analyses, as they were not diagnosed with HIV at the
ime of questionnaire completion. For heterosexual men and women re-
pectively, 48.4% and 48.7% were of Black or mixed African ethnicity,
1.6% and 17.1% of Black or mixed Caribbean ethnicity, 31.4% and
4.4% of white ethnicity, and 8.6% and 9.8% of any other ethnicity.
he median age was 29 (interquartile range IQR 25–37) and 26 (IQR
2–32) years for heterosexual men and women respectively. Overall,
4.0% of heterosexual men and 44.2% of women were born in the UK,
8.3% and 56.3% respectively had a university degree, and 74.5% and
0.8% were attending a clinic in London ( Tables 1 and 2 ). 
In total, 3258 people living with HIV participated in the ASTRA study
response rate was 64% of eligible patients approached), of whom 373
ere heterosexual men and 637 were women. For heterosexual men and
omen respectively, 52.2% and 68.5% were of Black or mixed African
thnicity, 7.5% and 5.7% of Black or mixed Caribbean ethnicity, 33.1%
nd 20.2% of white ethnicity, and 7.2% and 5.6% of any other ethnicity.
he median age was 47 (IQR 41–53) and 42 (IQR 35–48) respectively.
he proportion of heterosexual men born in the UK, reporting a uni-
ersity degree level of education, and attending a clinic in London was
8.4%, 35.4%, and 76.9% respectively. The corresponding percentages
or women were 18.7%, 31.1%, and 79.3% ( Tables 1 and 2 ). 
revalence of recreational drug use 
Prevalence of drug use is shown in Fig. 1 . As the mean age was
ubstantially younger for AURAH than ASTRA participants, the age-
tandardized prevalence of drug use is described here and also shown
n Fig. 1 for the three main drug use measures. The prevalence of us-
ng at least one recreational drug in the past three months was 22.9%
nd 17.1% among HIV-negative and HIV-positive heterosexual men, and
5.3% and 7.1% among HIV-negative and HIV-positive women respec-
ively. Five percent of HIV-negative heterosexual men and 3.8% of HIV-
ositive heterosexual men, and 2.6% of HIV-negative women and 0.6%
f HIV-positive women reported poly drug use. For HIV-negative men,
annabis was the drug most commonly used in the past three months
17.9%, age standardized) followed by use of cocaine (8.5%) and MDMA
4.6%). For HIV-positive men, cannabis and cocaine were again the most
revalent (13.1% and 6.1% respectively), followed by crack cocaine
2.7%). Similarly, for HIV-negative women, cannabis (12.4%), cocaine
5.1%) and MDMA (3.0%) were the drugs most commonly used in the
ast three months. For HIV-positive women, cannabis (4.7%) and co-
aine (1.6%) were the most commonly used drugs, with all other drugs
aving a prevalence of < 1%. The prevalence of drug use associated with
hemsex in gay communities in the past three months was very low
mong HIV-negative heterosexual men (1.0%) and women (0.2%) and
as zero among HIV-positive heterosexual men and women. 
The numbers of heterosexual men and women who reported injec-























































Unadjusted and adjusted associations of demographic, socio-economic and lifestyle factors with three measures of recreational drug use in the past three months among HIV-negative heterosexual men in AURAH and 
heterosexual men living with HIV in ASTRA. 
N = 470 HIV-negative heterosexual men in AURAH n N = 373 HIV-positive heterosexual men in ASTRA 
Any recreational drug use Use of cannabis Use of cocaine Any recreational drug use Use of cannabis Use of cocaine 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] 
Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c 
Age: 
< 25 89 36.0% 3.06 [1.37, 6.82] 33.7% 2.87 [1.28, 6.42] 3.4% 0.32 [0.09, 1.14] 3 33.3% 33.3% 0.0% 
25-29 152 32.9% 2.80 [1.27, 6.14] 23.7% 2.01 [0.90, 4.50] 15.8% 1.49 [0.73, 3.06] 6 16.7% 16.7% 16.7% 
30-34 70 28.6% 2.43 [1.05, 5.62] 22.9% 1.94 [0.82, 4.62] 8.6% 0.70 [0.30, 1.66] i 20 15.0% 1.15 [0.49, 2.71] k 10.0% 1.20 [0.45, 3.21] k 10.0% 3.91 [1.03, 14.84] k 
35-39 64 20.3% 1.73 [0.71, 4.23] 17.2% 1.46 [0.58, 3.69] 6.3% 1 j 44 22.7% 1.52 [0.81, 2.84] 18.2% 1.59 [0.77, 3.28] 4.6% 1.72 [0.36, 8.26] 
40-44 34 23.5% 2.00 [0.76, 5.26] 2.9% 1.46 [0.03, 1.99] 20.6% 0.022 63 17.5% 1.17 [0.63, 2.17] 11.1% 0.97 [0.44, 2.13] 3.2% 1.20 [0.25, 5.82] 
45 + 51 11.8% 1 11.8% 1 3.9% 0.541 227 15.0% 1 11.5% 1 2.6% 1 
0.019 0.045 0.002 0.012 0.004 0.638 0.631 0.488 0.628 0.155 0.241 
< .001 < .001 < .001 < .001 0.884 0.313 0.318 0.300 0.361 0.157 0.078 
Ethnicity o : 
Black/m African 225 17.8% 1 15.1% 1 2.7% 1 188 5.9% 1 4.3% 1 0.5% 1 
Black/m Caribbean 54 38.9% 2.04 [1.30, 3.22] 31.5% 1.91 [1.13, 3.20] 5.6% / 27 33.3% / 29.6% \ 3.7% \ 
White 146 40.4% 2.15 [1.52, 3.03] 28.1% 1.74 [1.16, 2.60] 23.3% 8.60 [3.68, 20.09] 119 28.6% 5.40 [2.83, 10.31] 20.2% 5.23 [2.41, 11.34] 8.4% 20.04 [2.54, 158.02] 
Other ethnicity 40 22.5% 1.22 [0.66, 2.28] 20.0% 1.26 [0.64, 2.48] 7.5% 2.39 [0.78, 7.29] p 26 19.2% 4.58 [2.20, 9.54] p 15.4% 5.40 [2.32, 12.58] p 3.9% 6.18 [0.61, 62.15] p 
< .001 < .001 0.006 0.028 < .001 < .001 < .001 < .001 < .001 < .001 0.005 0.008 
London clinic site: 
Yes 350 29.7% 1 23.7% 1 11.1% 1 287 16.7% 1 12.5% 1 3.1% m 
No 120 21.7% 0.70 [0.48, 1.02] 15.0% 0.60 [0.37, 0.95] 6.7% 0.52 [0.24, 1.13] 86 14.0% 0.91 [0.51, 1.62] 10.5% 0.91 [0.46, 1.80] 4.7% 
0.089 0.062 0.045 0.03 0.158 0.101 0.539 0.402 0.604 0.778 0.507 
University Education: 
Yes 274 22.6% 1 17.2% 1 7.7% 1 132 8.3% 1 5.3% 1 4.6% 1 
No/missing 196 34.7% 1.54 [1.15, 2.06] 27.6% 1.60 [1.13, 2.26] 13.3% 1.71 [0.99, 2.96] 241 20.3% 2.51 [1.36, 4.65] 15.8% 3.06 [1.41, 6.63] 2.9% 0.67 [0.23, 1.93] 
0.004 0.003 0.007 0.007 0.046 0.056 0.003 0.003 0.003 0.005 0.409 0.459 
Employed: 
Yes 340 25.9% 1 19.7% 1 11.2% 1 166 12.1% 1 9.6% 1 4.2% 1 
No d /missing 130 32.3% 1.06 [0.76, 1.46] 26.2% 1.07 [0.73, 1.58] 6.9% 0.52 [0.24, 1.10] 207 19.3% 1.73 [1.05, 2.84] 14.0% 1.56 [0.88, 2.77] 2.9% 0.78 [0.27, 2.28] 
0.164 0.737 0.128 0.725 0.169 0.088 0.057 0.032 0.198 0.125 0.49 0.656 


























































N = 470 HIV-negative heterosexual men in AURAH n N = 373 HIV-positive heterosexual men in ASTRA 
Any recreational drug use Use of cannabis Use of cocaine Any recreational drug use Use of cannabis Use of cocaine 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] 
Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c 
Enough money e : 
Always 275 28.7% 1 21.5% 1 10.9% 1 106 10.4% 1 7.6% 1 1.89% 
Mostly 113 25.7% 0.88 [0.61, 1.28] 20.4% 0.93 [0.60, 1.45] 13.3% 1.14 [0.63, 2.07] 80 16.3% 1.51 [0.72, 3.19] 11.3% 1.44 [0.58, 3.56] 6.3% 1 
At times/no 78 26.9% 0.98 [0.66, 1.47] 23.1% 1.13 [0.72, 1.77] 2.6% 0.25 [0.06, 1.00] 173 20.2% 1.90 [1.01, 3.59] 15.6% 2.02 [0.95, 4.28] 3.5% 0.88 [0.30, 2.55] l 
0.818 0.81 0.903 0.782 0.042 0.115 0.098 0.133 0.131 0.166 0.259 0.809 
0.638 0.774 0.85 0.721 0.101 0.063 0.032 0.041 0.044 0.057 0.606 
Housing: 
Home owner 71 21.1% 1 18.3% 1 5.6% 1 77 14.3% 1 10.4% 1 6.5% m 
Renting 286 26.2% 1.06 [0.65, 1.74] 18.9% 0.85 [0.49, 1.46] 11.2% 1.93 [0.72, 5.17] 213 15.5% 1.01 [0.53, 1.93] 12.7% 1.12 [0.52, 2.44] 1.9% 
Other f 106 35.9% 1.25 [0.73, 2.14] 30.2% 1.12 [0.62, 2.03] 9.4% 1.56 [0.50, 4.79] 69 21.7% 1.35 [0.66, 2.77] 13.0% 1.10 [0.45, 2.70] 5.8% 
0.068 0.568 0.042 0.340 0.368 0.392 0.405 0.528 0.850 0.957 0.368 
0.024 0.332 0.034 0.445 0.524 0.625 0.236 0.398 0.618 0.837 1.000 
Relationship q : 
Yes 302 19.5% 1 14.9% 1 7.0% 1 253 11.5% 1 8.7% 1 3.2% 1 
No/missing 168 42.3% 1.91 [1.41, 2.59] 33.3% 1.92 [1.34, 2.74] 15.5% 2.30 [1.24, 4.26] 120 25.8% 2.33 [1.48, 3.66] 19.2% 2.28 [1.33, 3.90] 4.2% 1.42 [0.48, 4.21] 
< .001 < .001 < .001 < .001 0.003 0.008 < .001 < .001 0.004 0.003 0.763 0.524 
High levels of social support g : 
Yes 330 27.6% 1 21.5% 1 10.6% 1 229 12.7% 1 10.5% 1 3.9% 1 
No 120 31.7% 1.19 [0.87, 1.61] 24.2% 1.17 [0.81, 1.69] 10.0% 0.97 [0.52, 1.81] 126 23.8% 1.83 [1.15, 2.89] 15.9% 1.47 [0.85, 2.56] 3.2% 0.74 [0.23, 2.39] 
0.396 0.278 0.550 0.412 0.853 0.936 0.007 0.010 0.140 0.172 0.717 0.618 
Current smoker: 
No/missing 367 19.1% 1 14.4% 1 6.3% 1 258 4.7% 1 2.3% 1 1.2% 1 
Yes 103 58.3% 2.99 [2.29, 3.91] 46.6% 3.14 [2.26, 4.36] 23.3% 3.59 [2.11, 6.12] 115 41.7% 8.81 [4.87, 15.93] 33.9% 14.35 [6.25, 32.95] 8.7% 6.87 [1.93, 24.44] 
< .001 < .001 < .001 < .001 < .001 < .001 < .001 < .001 < .001 < .001 < .001 0.003 
Higher-risk drinking h : 
No/missing 408 24.3% 1 19.6% 1 6.1% 1 329 14.6% 1 11.9% 1 2.7% m 
Yes 62 50.0% 1.89 [1.39, 2.57] 33.9% 1.56 [1.04, 2.34] 35.5% 5.92 [3.54, 9.92] 44 27.3% 1.88 [1.09, 3.24] 13.6% 1.15 [0.52, 2.56] 9.1% 
< .001 < .001 0.011 0.033 < .001 < .001 0.032 0.024 0.733 0.724 0.054 
a p-value by pearson 𝜒2 test or Fisher’s exact test, followed by p-value for test for trend for ordered categorical variables (age, financial security, and housing). 
b Adjusted for age as a continuous variable. 
c Overall p-value for heterogeneity by Wald test in modified Poisson regression, followed by p-value for test for trend for ordered categorical variables (age, financial security, and housing). 
d Including full time student, unemployed, permanently/temporarily sick, caretaker, retired. 
e Enough money to cover basic needs (e.g. food, heating). 
f Including unstable housing: temporary accommodation (hostel, shelter, bed and breakfast, squat), staying with partner/friend(s)/family, and homeless. 
g Having a supportive network of individuals in one’s life was assessed using a modified version of the Duke-UNC Functional Social Support Questionnaire ( Broadhead, Gehlbach, de Gruy, & Kaplan, 1988 ) (with 
options: much less than I would like (1); less than I would like (2); some, would like more (3); almost as much as I would like (4); as much as I would like (5)). The total score across the five questions for each 
participant was generated. A total score of 21-25 was considered to indicate high levels of a supportive network and scores of 5-20 were considered to indicate lower levels of a supportive network. 
h Higher-risk drinking is based on the first two questions of the WHO AUDIT-C questionnaire. Higher risk drinking is indicated by a score of ≥ 6 and lower risk drinking/no alcohol consumption by a score of < 6. 
( Babor, Higgins-Biddle, Saunders, & Monteiro, 2001 ) 
i Ages 30-39 years; combined age groups due to small cell counts. 
j Age 40 plus years; combined age groups due to small cell counts. 
k Ages < 25 to 34 years; combined age groups due to small cell counts. 
l Always/mostly enough money; combined categories due to small cell counts. 
m Not calculated due to small cell counts. 
n Individuals who had not been diagnosed with HIV at the time of the AURAH questionnaire completion. Four heterosexual men tested HIV-positive on the day of the AURAH questionnaire. 
o Individuals reporting Black or mixed African ethnicity were categorised as Black/m African; those reporting Black or mixed Caribbean ethnicity were categorised as Black/m Caribbean. All white ethnic groups 
were categorised as white ethnicity and individuals from all other ethnic groups were categorised as other ethnicity. 
p Black/m Caribbean and other ethnic groups; combined ethnic groups due to small cell counts. 

























































Unadjusted and adjusted associations of demographic, socio-economic and lifestyle factors with three measures of recreational drug use in the past three months among HIV-negative women in AURAH and women 
living with HIV in ASTRA. 
N = 676 HIV-negative women in AURAH n N = 637 HIV-positive women in ASTRA 
Any recreational drug use Use of cannabis Use of cocaine Any recreational drug use Use of cannabis Use of cocaine 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] 
Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c 
Age: 
< 25 287 22.3% 3.20 [1.05, 9.73] 19.2% 2.64 [1.10, 6.36] 7.7% 5.29 [0.72, 38.62] 10 40.0% 20.0% 10.0% 
25-29 140 23.6% 3.38 [1.09, 10.5] 15.0% 2.07 [0.81, 5.26] 9.3% 6.41 [0.85, 48.06] 44 11.4% 11.4% 0.0% 
30-34 103 6.8% 0.97 [0.26, 3.60] 4.9% 1.08 [0.40, 2.92] i 2.9% 2.49 [0.31, 20.36] i 79 1.3% 1.11 [0.52, 2.39] k 0.0% 1.39 [0.53, 3.64] k 1.3% 1.19 [0.20, 7.03] k 
35-39 63 15.9% 2.28 [0.66, 7.80] 12.7% 1 j 4.8% 1 j 98 6.1% 0.91 [0.37, 2.25] 4.1% 1.07 [0.34, 3.41] 3.1% 2.42 [0.50, 11.79] 
40-44 26 7.7% 1.10 [0.20, 6.18] 7.7% 0.005 0.0% 0.087 134 6.7% 0.99 [0.45, 2.19] 4.5% 1.18 [0.43, 3.24] 1.5% 1.18 [0.20, 6.98] 
45 + 43 7.0% 1 7.0% < .001 2.3% 0.012 237 6.8% 1 3.8% 1 1.3% 1 
0.001 0.004 0.007 0.199 0.004 0.981 0.012 0.927 0.286 0.710 
< .001 0.001 0.001 0.025 0.242 0.855 0.157 0.553 0.514 0.582 
Ethnicity o : 
Black/m African 325 11.4% 1 10.2% 1 2.2% 1 420 1.0% 1 0.2% 1 0.5% 
Black/m Caribbean 114 21.9% 2.10 [1.33, 3.32] 21.1% 2.27 [1.40, 3.66] 4.4% \ 35 11.4% \ 11.4% \ 0.0% m 
White 163 30.1% 2.80 [1.92, 4.09] 19.0% 2.00 [1.28, 3.12] 16.6% 8.01 [3.58, 17.92] 124 24.2% 33.03 [10.23, 106.62] 16.1% 65.90 [8.95, 485.08] 5.7% 
Other ethnicity 65 13.9% 1.50 [0.77, 2.93] 10.8% 1.32 [0.61, 2.82] 4.6% 2.32 [0.86, 6.27] p 34 14.7% 15.86 [4.31, 58.29] p 8.8% 35.14 [4.28, 288.66] p 5.9% 
< .001 < .001 0.006 0.003 < .001 < .001 < .001 < .001 < .001 < .001 < .001 
London clinic site: 
Yes 411 20.7% 1 16.6% 1 8.0% 1 505 6.3% 1 4.0% 1 1.8% m 
No 265 13.2% 0.61 [0.42, 0.88] 10.2% 0.59 [0.39, 0.90] 3.4% 0.40 [0.19, 0.82] 132 9.1% 1.57 [0.80, 3.07] 6.1% 1.61 [0.69, 3.78] 1.5% 
0.013 0.008 0.020 0.014 0.015 0.013 0.267 0.191 0.295 0.274 0.593 
University Education: 
Yes 380 14.5% 1 11.1% 1 6.1% 1 198 3.5% 1 2.0% 1 1.0% m 
No/missing 295 22.0% 1.51 [1.09, 2.09] 18.0% 1.60 [1.10, 2.33] 6.4% 1.07 [0.59, 1.93] 439 8.4% 2.72 [1.16, 6.35] 5.5% 3.58 [1.09, 11.78] 2.1% 
0.011 0.013 0.010 0.013 0.836 0.826 0.024 0.021 0.050 0.036 0.517 
Employed: 
Yes 361 18.6% 1 13.0% 1 8.3% 1 288 4.9% 1 3.47% 1 1.0% 1 
No d /missing 315 16.8% 0.74 [0.52, 1.08] 15.2% 0.97 [0.64, 1.49] 3.8% 0.36 [0.17, 0.74] 349 8.6% 1.82 [0.96, 3.45] 5.2% 1.60 [0.73, 3.53] 2.3% 1.97 [0.51, 7.58] 
0.556 0.116 0.408 0.899 0.016 0.006 0.064 0.065 0.302 0.245 0.228 0.321 


























































N = 676 HIV-negative women in AURAH n N = 637 HIV-positive women in ASTRA 
Any recreational drug use Use of cannabis Use of cocaine Any recreational drug use Use of cannabis Use of cocaine 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
N 
% Age-adjusted b % Age-adjusted b % Age-adjusted b 
p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] p-value a PR[95% CI] 
Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c Overall p-value c 
Enough money e : 
Always 318 15.7% 1 11.3% 1 6.9% 1 133 6.8% 1 3.8% 1 2.3% 
Mostly 200 22.0% 1.37 [0.95, 1.96] 17.5% 1.51 [0.99, 2.31] 7.5% 1.06 [0.56, 1.99] 147 8.8% 1.46 [0.62, 3.41] 6.1% 2.01 [0.63, 6.37] 2.0% 1 
At times/no 148 16.9% 1.10 [0.71, 1.71] 15.5% 1.41 [0.86, 2.29] 3.4% 0.52 [0.20, 1.36] 334 6.3% 0.97 [0.44, 2.17] 4.2% 1.32 [0.44, 3.96] 1.5% 0.58 [0.16, 2.03] l 
0.181 0.228 0.123 0.140 0.243 0.358 0.595 0.473 0.570 0.430 0.775 0.392 
0.495 0.414 0.125 0.091 0.209 0.233 0.685 0.726 0.968 0.843 0.547 
Housing: 
Home owner 155 9.5% 1 6.0% 1 6.0% 1 77 7.8% 1 6.7% 1 1.1% m 
Renting 682 19.7% 1.42 [0.69, 2.89] 15.7% 1.81 [0.74, 4.45] 6.8% 0.70 [0.25, 1.97] 213 7.9% 1.03 [0.45, 2.36] 4.6% 0.66 [0.26, 1.69] 2.4% 
Other f 292 17.7% 1.12 [0.52, 2.42] 14.5% 1.49 [0.58, 3.85] 5.4% 0.45 [0.13, 1.53] 69 2.7% 0.36 [0.10, 1.32] 2.7% 0.38 [0.10, 1.43] 0.0% 
0.087 0.325 0.067 0.314 0.792 0.372 0.156 0.195 0.412 0.355 0.231 
0.268 0.597 0.171 0.992 0.712 0.157 0.134 0.064 0.184 0.133 0.468 
Relationship q 
Yes 466 14.8% 1 11.8% 1 4.7% 1 346 7.8% 1 4.9% 1 2.3% 1 
No/missing 210 24.3% 1.57 [1.14, 2.16] 19.1% 1.54 [1.07, 2.23] 9.5% 1.89 [1.04, 3.43] 291 5.8% 0.80 [0.43, 1.46] 3.8% 0.80 [0.37, 1.73] 1.0% 0.53 [0.13, 2.15] 
0.003 0.006 0.012 0.021 0.017 0.036 0.331 0.461 0.487 0.577 0.216 0.372 
High levels of social support g : 
Yes 486 16.3% 1 12.4% 1 6.6% 1 370 6.5% 1 3.8% 1 1.9% 1 
No 176 23.3% 1.44 [1.03, 2.01] 19.9% 1.61 [1.10, 2.36] 5.7% 0.89 [0.45, 1.77] 243 7.8% 1.28 [0.70, 2.36] 5.4% 1.46 [0.67, 3.19] 1.7% 1.05 [0.29, 3.77] 
0.038 0.032 0.014 0.013 0.674 0.740 0.527 0.420 0.355 0.336 0.823 0.942 
Current smoker: 
No/missing 534 10.1% 1 7.5% 1 2.8% 1 570 2.3% 1 1.1% m 1.1% m 
Yes 142 46.5% 4.28 [3.15, 5.81] 38.7% 4.79 [3.34, 6.87] 19.0% 6.39 [3.50, 11.65] 67 46.3% 18.3 [9.97, 33.46] 32.8% 7.5% 
< .001 < .001 < .001 < .001 < .001 < .001 < .001 < .001 < .001 0.003 
Higher-risk drinking h : 
No/missing 643 16.2% 1 13.2% 1 4.5% m 624 6.6% m 4.2% m 1.8% m 
Yes 33 48.5% 2.87 [1.94, 4.25] 30.3% 2.19 [1.26, 3.82] 39.4% 13 23.1% 15.4% 0.0% 
< .001 < .001 0.006 0.006 < .001 0.054 0.051 1.000 
a p-value by pearson 𝜒2 test or Fisher’s exact test, followed by p-value for test for trend for ordered categorical variables (age, financial security, and housing). 
b Adjusted for age as a continuous variable. 
c Overall p-value for heterogeneity by Wald test in modified Poisson regression, followed by p-value for test for trend for ordered categorical variables (age, financial security, and housing). 
d Including full time student, unemployed, permanently/temporarily sick, caretaker, retired. 
e Enough money to cover basic needs (e.g. food, heating). 
f Including unstable housing: temporary accommodation (hostel, shelter, bed and breakfast, squat), staying with partner/friend(s)/family, and homeless. 
g Having a supportive network of individuals in one’s life was assessed using a modified version of the Duke-UNC Functional Social Support Questionnaire ( Broadhead et al., 1988 ) (with options: much less than I 
would like (1); less than I would like (2); some, would like more (3); almost as much as I would like (4); as much as I would like (5)). The total score across the five questions for each participant was generated. A 
total score of 21-25 was considered to indicate high levels of a supportive network and scores of 5-20 were considered to indicate lower levels of a supportive network. 
h Higher-risk drinking is based on the first two questions of the WHO AUDIT-C questionnaire. Higher risk drinking is indicated by a score of ≥ 6 and lower risk drinking/no alcohol consumption by a score of < 6. 
( Babor et al., 2001 ). 
i Ages 30-39 years; combined age groups due to small cell counts. 
j Age 40 plus years; combined age groups due to small cell counts. 
k Ages < 25 to 34 years; combined age groups due to small cell counts. 
l Always/mostly enough money; combined categories due to small cell counts. 
m Not calculated due to small cell counts. 
n Individuals who had not been diagnosed with HIV at the time of the AURAH questionnaire completion. One woman tested HIV-positive on the day of the AURAH questionnaire. 
o Individuals reporting Black or mixed African ethnicity were categorised as Black/m African; those reporting Black or mixed Caribbean ethnicity were categorised as Black/m Caribbean. All white ethnic groups 
were categorised as white ethnicity and individuals from all other ethnic groups were categorised as other ethnicity. 
p Black/m Caribbean and other ethnic groups; combined ethnic groups due to small cell counts. 
q Participants were asked ‘Are you currently in an ongoing relationship with a partner (wife/husband or civil partner or girlfriend/boyfriend)? 
7
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Fig. 1. Prevalence of recreational drug use in the past three months (scale is to 60%). Figures show crude prevalence; age standardized prevalence for any drug 
use, poly drug use and use of drugs associated with chemsex are given in text boxes. Chemsex drug use = use of drugs (one or more of mephedrone, gamma- 




























































e  rosexual man, five HIV-positive heterosexual men, two HIV-negative
omen, and one HIV-positive woman. 
omparison with GBMSM participants 
To provide comparative information, Fig. 1 also shows the preva-
ence of recreational drug use among GBMSM participants. Prevalence
f drug use overall, poly drug use, use of drugs associated with chem-
ex and use of most individual drugs was considerably higher among
BMSM compared to heterosexuals. Around a quarter of HIV-negative
nd HIV-positive GBMSM reported poly drug use, while 20.5% of HIV-
egative and 19.0% of HIV-positive GBMSM reported use of drugs asso-
iated with chemsex (standardized for age). 
ocio-economic and lifestyle factors and recreational drug use among 
IV-negative and HIV-positive heterosexual men 
Among HIV-negative heterosexual men, younger age ( < 35 years),
on-university degree level of education, being single, smoking, higher
isk alcohol consumption and, to a lesser extent, London clinic site
as associated with any drug use in unadjusted analysis and analy-
is adjusted for age. HIV-negative heterosexual men of Black/mixed
aribbean or white ethnicity were much more likely to report any drug
se than men of Black or mixed African ethnicity, including after adjust-
ng for age ( Table 1 ). There was some indication of an association with
ore unstable housing but this was attenuated after age adjustment.
ther socio-economic factors (employment, financial hardship, and sup-
ortive network) were not associated with drug use overall. The associ-
tions with cannabis use were similar. Again, a broadly similar pattern
f associations was observed for cocaine use, although older rather than
ounger men were more likely to report using cocaine. In addition, fi-
ancial security was associated with cocaine use in unadjusted, but not
ge-adjusted analysis ( Table 1 ). 8 Among HIV-positive heterosexual men, non-university degree level
f education, non-employment, being single, financial hardship, lower
evels of a supportive network, smoking, and higher risk alcohol con-
umption was associated with any drug use in unadjusted and age-
djusted analysis. HIV-positive heterosexual men of white or any other
thnicity were much more likely to report any drug use than men
f Black or mixed African ethnicity, including after adjusting for age
 Table 1 ). The pattern of associations with cannabis was broadly sim-
lar to that found for any drug use, although employment, supportive
etwork, and higher risk drinking was not associated with cannabis in
nadjusted or age-adjusted analysis. There were fewer associations with
ocaine use, in particular there was no relationship with education or
nancial hardship ( Table 1 ). 
ocio-economic and lifestyle factors and recreational drug use among 
IV-negative and HIV-positive women 
Among HIV-negative women, younger age ( < 30 years), London
linic site, non-university degree level of education, being single, smok-
ng, higher risk alcohol consumption, and lower levels of a support-
ve network was associated with any drug use in unadjusted and age-
djusted analysis. HIV-negative women of Black/mixed Caribbean or
hite ethnicity were much more likely to report any drug use than
omen of Black or mixed African ethnicity, including after adjusting
or age ( Table 2 ). Similar associations to that found for any drug use
ere observed with cannabis use and, with the exception of levels of
ducation and a supportive network, with cocaine use. Being employed
as also associated with cocaine use in unadjusted and age-adjusted
nalysis ( Table 2 ). 
Among women living with HIV, non-university degree level of ed-
cation and smoking was associated with any drug use in unadjusted
nd age-adjusted analysis. HIV-positive women of white or any other
thnicity were much more likely to report any drug use than women
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Fig. 2. Adjusted associations of any drug use and cannabis use with depression and anxiety symptoms among HIV-negative and HIV-positive heterosexual men and 





































































n  f Black or mixed African ethnicity, including after adjusting for age
 Table 2 ). Younger age ( < 25 years) was associated with any drug use in
he 𝜒2 analysis but the number of women in this age group was small
nd there was no association when combining age groups less than 35 in
he unadjusted Poisson model. There was some evidence for an effect of
on-employment and higher-risk alcohol consumption but the number
f women who reported the latter was small. Similar associations to that
ound for any drug use were observed with cannabis use. For cocaine
se, the pattern was broadly similar but there was no association with
ge, education and higher risk drinking. 
ecreational drug use and symptoms of depression and anxiety among 
IV-negative and HIV-positive heterosexual men 
Among HIV-negative heterosexual men, the prevalence of symptoms
f anxiety and depression was 7.0% and 4.5% respectively. No asso-
iations were observed for any drug use, cannabis use, or cocaine use
ith depressive symptoms or symptoms of anxiety in unadjusted or ad-
usted analysis ( Fig. 2 ), although confidence intervals were wide. Among
IV-positive heterosexual men, symptom prevalence was much higher:
6.5% and 21.2% for depression and anxiety respectively. Any drug use
nd cannabis use was strongly associated with depressive symptoms in
nadjusted and adjusted analysis. Any drug use but not cannabis use
as associated with symptoms of anxiety in unadjusted and adjusted
nalysis ( Fig. 2 ). Due to small numbers associations with cocaine use
ere not investigated. 
ecreational drug use and symptoms of depression and anxiety among 
IV-negative and HIV-positive women 
Among HIV-negative women, prevalence of symptoms was 14.8%
or depression and 11.7% for anxiety. Any drug use was associated with
epression in unadjusted and adjusted analysis. There was no signif-
cant association with anxiety ( Fig. 2 ). Cannabis use was not associ-
ted with depression or anxiety among HIV-negative women. Cocaine
se was not associated with depression or anxiety among HIV-negative
omen. Among HIV-positive women, there was a high prevalence of
epression and anxiety symptoms (30.0% and 25.8% respectively). Any9 rug use and cannabis use was associated with both depressive and anx-
ety symptoms in unadjusted and adjusted analysis ( Fig. 2 ). Cocaine
se was not associated with depression or anxiety among HIV-positive
omen. 
ecreational drug use and sexual behavior and attitudes among 
IV-negative and HIV-positive heterosexual men 
Among HIV-negative heterosexual men, 43.4% reported CLS with a
on-regular partner and just under a third reported CLS with two or
ore partners in the past three months. The prevalence of CLS with a
on-regular partner was elevated among those who reported any drug
se, cannabis use and cocaine use ( Table 3 ). Only associations with
annabis and cocaine remained after adjustment for socio-demographic
actors. The prevalence of CLS with two or more partners was elevated
mong those who reported any drug use and cannabis use ( Table 3 ). The
ssociation with cannabis use was significant, and there was some evi-
ence for the association with any drug use, in adjusted analysis. For the
ssociations between any drug use and measures of CLS, the observed
ttenuation in adjusted analysis appeared to be driven primarily by ad-
ustment for the relationship status measure; men not in an ongoing re-
ationship were more likely to report recent drug use and CLS. Evidence
f associations with low self-efficacy for sexual safety was found for any
rug use and cocaine use in unadjusted analysis, but the association
ith any drug use was attenuated after adjustment. Two HIV-negative
eterosexual men reported transactional sex for money or drugs in the
ast three months, neither of whom reported any drug use in the past
hree months. 
Among HIV-positive heterosexual men, the prevalence of CLS mea-
ures was much lower. Thirteen individuals (3.5%) indicated CLS with
 non-regular partner and 9 (2.4%) reported CLS with two or more
artners in the past three months. Overall, 26.8% of HIV-positive het-
rosexual men reported low self-efficacy for sexual safety. There was
n association between cocaine use (versus no cocaine use) and CLS
ith a non-regular partner (15.4% vs. 3.1%; p = 0.017). Measures
f drug use were not associated with CLS with two or more part-
ers or low self-efficacy for sexual safety in unadjusted analysis. Two
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Table 3 
Unadjusted and adjusted associations of drug use measures with measures of CLS and sexual attitudes among HIV-negative heterosexual men and women in 
the AURAH study. 
N = 470 heterosexual men a 
CLS with non-regular partner (past 3 months) 
( n = 204; 43.4%) 
CLS with two or more partners (past 3 months) 
( n = 144; 30.6%) 
Lower self-efficacy for sexual safety 
( n = 660; 33.8%) 
% p-value a 
Adjusted b 
PR [95% CI] 
p-value c % p-value a 
Adjusted b 
PR [95% CI] 
p-value c % p-value a 
Adjusted b 
PR [95% CI] 
p-value c 



















1.16 [0.88, 1.53] 
0.301 



















1.00 [0.73, 1.35] 
0.977 



















1.47 [1.04, 2.07] 
0.028 
N = 676 women a 
CLS with non-regular partner (past 3 months) 
( n = 192; 28.4%) 
CLS with two or more partners (past 3 
months) 
( n = 114; 16.9%) 
Lower self-efficacy for sexual safety 
( n = 208; 30.8%) 
% p-value a 
Adjusted b 
PR [95% CI] 
p-value c % p-value a 
Adjusted b 
PR [95% CI] 
p-value c % p-value a 
Adjusted b 
PR [95% CI] 
p-value c 



















1.44 [1.09, 1.91] 
0.011 



















1.33 [0.98, 1.81] 
0.070 



















1.64 [1.12, 2.39] 
0.011 
CLS = condomless sex. 
a Individuals who had not been diagnosed with HIV at the time of the AURAH questionnaire completion. Four heterosexual men and one woman tested 
HIV-positive on the day of the AURAH questionnaire. 
b Adjusted for: age (as a continuous variable), ethnicity (Black/mixed African or other ethnicity), university education, ongoing relationship status, and 
London clinic site. 






































o  en reported transactional sex for money or drugs in the past three
onths, neither of whom reported any drug use in the past three
onths. 
ecreational drug use and sexual behavior and attitudes among 
IV-negative and HIV-positive women 
Among HIV-negative women, 28.4% reported CLS with a non-
egular partner and 16.9% reported two or more CLS partners in the
ast three months. Those who reported any drug use, cannabis use, and
ocaine use were much more likely (approximately 1.5 to two-fold) to
eport CLS with a non-regular partner and two to three times more likely
o report CLS with two or more partners, in unadjusted and adjusted
nalysis ( Table 3 ). Women who reported any drug use and cocaine use
ere more likely to report low self-efficacy for sexual safety, in unad-
usted and adjusted analysis. Seven HIV-negative women reported trans-
ctional sex for money or drugs in the past three months. Measures of
ny drug use, cannabis use, and cocaine use were all associated with an
ncreased prevalence of transactional sex (for money or drugs) in uni-
ariable analysis: any drug use 4.2% vs. 0.4%; cannabis use 5.3% vs.
.3%; cocaine use 4.8% vs. 0.8%; all p-values ≤ 0.01. 10 Among HIV-positive women, the prevalence of CLS measures was
ow. Thirteen women (2.0%) indicated CLS with a non-regular partner
nd 17 (2.7%) reported CLS with two or more partners in the past three
onths. Overall, 30.8% of women reported low self-efficacy for sexual
afety. There was an association between any drug use (versus no drug
se) and CLS with a non-regular partner (6.8% vs. 1.7%; p = 0.02),
nd between cocaine use and CLS with a non-regular partner (18.2% vs.
.8%; p < 0.001). Measures of drug use were not associated with CLS with
wo or more partners or low self-efficacy for sexual safety in unadjusted
nalysis. Two women reported transactional sex for money or drugs,
oth of whom reported drug use in the past three months (not cannabis
or cocaine). 
iscussion 
This study assessed recreational drug use among HIV-negative het-
rosexual men and women recruited from sexual health clinics and HIV-
ositive heterosexual men and women recruited from HIV outpatient
entres. Cannabis, cocaine, and among HIV-negative men and women,
DMA, were the most commonly used recreational drugs. Prevalence
f use of drugs associated with chemsex in gay communities was very






























































































































r  ow in heterosexuals. A broadly similar pattern of associations with
rug use was apparent across the four sample groups. Younger age,
lack/mixed Caribbean and white ethnicity, attending a study clinic in
ondon, non-university degree level of education, non-employment, be-
ng single, lower levels of a supportive network, smoking, and higher
isk alcohol consumption tended to be associated with any recreational
rug use and cannabis use. For cocaine use, the pattern of associations
as broadly similar but notable differences were observed with age and
ocio-economic status. In some cases, cocaine use was more prevalent
mong older rather than younger people. Prevalence of cocaine use also
ended to differ less between education groups, rather than being more
revalent in those with lower levels of educational attainment, and
ended to be associated with employment and financial security. This
ay reflect the fact that cocaine has traditionally been popular as a stim-
lant among people in high-earning occupations ( Johnston, O’Malley,
achman & Schulenberg, 2008 ). In these heterosexual groups, there was
vidence of associations of recreational drug use with measures of re-
ent CLS, low self-efficacy for sexual safety and with symptoms of anxi-
ty and depression. Associations with sexual behavior were particularly
pparent among HIV-negative and HIV-positive women, and with poor
ental health among HIV-positive men and women. 
revalence and correlates of recreational drug use among heterosexual men 
nd women 
Two UK population-based studies have collected data on recreational
rug use: the Crime Survey for England and Wales (CSEW) and the Na-
ional Survey of Sexual Attitudes and Lifestyles (Natsal). In the CSEW
2017/2018), the prevalence of any recreational drug use in the past
ear was 11.8% for men and 6.2% for women ( ONSFlatley, 2018 ). In
atsal-3 (2010–2012), the prevalence of any recreational drug use in the
ast year among sexually active 16–44 year olds was 25.6% for men and
2.5% for women ( Paquette et al., 2017 ). These current findings sug-
est that the prevalence of recreational drug use may be higher among
eterosexuals attending sexual health clinics (28% in men and 18% in
omen; past three months) in England. When standardized by the age
istribution in Natsal, the prevalence of any drug use among 16–44 year
lds was 31.2% and 17.8% in HIV-negative men and women in AURAH
espectively. The equivalent estimates were 23.1% and 17.2% in HIV-
ositive men and women in ASTRA. However, other socio-demographic
actors may confound this comparison. There is a clear pattern across
tudies of heterosexual individuals in terms of the more common use
f cannabis, followed by cocaine and/or MDMA ( Bellis et al., 2008 ;
NSFlatley, 2018 ; Sumnall, Beynon, Conchie, Riley & Cole, 2007 ). This
s in line with findings from the current study, for both HIV-negative
nd HIV-positive heterosexual individuals. 
Studies of heterosexual men and women have found the follow-
ng socio-economic and lifestyle correlates with recreational drug use:
ounger age ( < 20 years) ( Hoare & Moon, 2010 ), white/mixed eth-
icity ( Paquette et al., 2017 ), lower levels of educational attainment
 Morley, Lynskey, Moran, Borschmann & Winstock, 2015 ), not being
mployed ( Morley et al., 2015 ), not being married/living alone ( Hoare
 Moon, 2010 ; Morley et al., 2015 ; Paquette et al., 2017 ), more fre-
uent alcohol consumption ( Hoare & Moon, 2010 ; Paquette et al., 2017 ),
nd smoking ( Morley et al., 2015 ; Paquette et al., 2017 ). Drug use
easures investigated included; any drug use ( Hoare & Moon, 2010 ;
orley et al., 2015 ), drug use other than, or in addition to, cannabis
 Paquette et al., 2017 ), use of cocaine/MDMA ( Morley et al., 2015 ),
nd use of cannabis/MDMA ( Morley et al., 2015 ), in the past year. Very
imilar associations were observed in the current study for HIV-negative
nd HIV-positive heterosexual men and HIV-negative and HIV-positive
omen, when examining cannabis, cocaine, and any drug use. In the
urrent study, individuals of different Black ethnicities were analysed
eparately (Black/mixed African and Black/mixed Caribbean), as recent
vidence in the UK suggests that sexual risk behaviors differ between
lack ethnic groups ( Coyle et al., 2018 ; Olonilua et al., 2008 ). Simi-11 arly, self-reported drug use prevalence was elevated in people of Black
r mixed Caribbean ethnicity (and white ethnicity) compared to people
f Black or mixed African ethnicity in the current study. 
se of drugs associated with chemsex among heterosexual men and women 
In the current UK study, the prevalence estimates of use of (one or
ore) drugs associated with chemsex in the past three months was very
ow for HIV-negative heterosexual men (1.3%) and women (0.3%). HIV-
ositive heterosexual men and women did not report use of drugs asso-
iated with chemsex. In contrast, about a fifth of GBMSM reported use
f drugs associated with chemsex. Similar findings were observed in
he Global Drug Survey (GDS), which recruited participants across 23
igh-income countries via social media (2012). Among 11,577 hetero-
exual men, the prevalence of having sex while on methamphetamine,
ephedrone, or GHB/GBL over the past year was 1.3%, 1.1%, and
.7% respectively. The equivalent prevalence among 4970 heterosexual
omen was 0.9%, 1.3%, and 0.5%. Therefore, it does not appear that
he phenomenon of chemsex is prevalent among heterosexuals. How-
ver, 29% of heterosexual men and 21% of heterosexual women in GDS
eported ever having engaged in sexualized drug use ( Lawn, Aldridge,
ia & Winstock, 2019 ). Other studies suggest that cannabis, MDMA, and
ocaine may be used for sexual purposes among heterosexual individ-
als ( Bellis et al., 2008 ; Sumnall et al., 2007 ). It is possible that the
otives for sexualized use of drugs among heterosexuals may differ to
hose for chemsex among GBMSM. For instance, heterosexuals may take
rugs to facilitate a sexual encounter or to relax more with a sexual part-
er ( Bellis et al., 2008 ; Sumnall et al., 2007 ), whereas chemsex drugs
ay be taken by some GBMSM to further facilitate prolonged sessions
days in length) of intense sexual activity ( Pakianathan, Lee, Kelly &
egazi, 2016 ; Stuart, 2019 ). 
ssociation of recreational drug use with sexual behavior/attitudes and 
ental health symptoms among heterosexual men and women 
Evidence from large high-income country studies and a meta-
nalysis suggest that among heterosexual men and women, any drug
se, cannabis/MDMA, and cocaine/MDMA is strongly associated with
LS ( Bellis et al., 2008 ; Brodbeck, Matter & Moggi, 2006 ; Morley et al.,
015 ; Paquette et al., 2017 ) and STI diagnosis ( Paquette et al., 2017 )
n the past year. Associations are also apparent after adjustment for
ocio-demographic factors ( Bellis et al., 2008 ; Morley et al., 2015 ;
aquette et al., 2017 ). Similar associations were observed in the cur-
ent study for both HIV-negative and HIV-positive heterosexual men,
nd HIV-negative and HIV-positive women. Associations were particu-
arly strong for women. 
For HIV-negative men and women, cocaine use was associated with
ow self-efficacy for sexual safety (did not strongly agree ‘I feel confi-
ent that, if I want to, I can make sure a condom is used during sex
ith any partner, in any situation.’) in adjusted analysis. This is in
ine with a substantial body of theoretical work postulating that drug
se, as well as alcohol use and depression, lowers one’s self-efficacy for
exual safety, with implications for sexual risk taking ( Bandura, 1997 ;
aciejewski, Prigerson & Mazure, 2000 ; Madden, 1991 ). For HIV-
egative women, reporting any drug use was also associated with low
elf-efficacy for sexual safety in adjusted analysis. Women may be more
usceptible to self-doubt and lack of assertiveness as a result of ingrained
exist norms ( Abramson, 2014 ), and may be particularly vulnerable
hen under the influence of substances. 
In a recent meta-analysis of seven studies (three U.S., two Australian,
ne Canadian, and one UK study), the pooled OR for the association be-
ween cannabis use during adolescence and depression in young adult-
ood was 1.37 (95% CI: 1.16, 1.62) ( Gobbi et al., 2019 ). Based on find-
ngs from three studies, the pooled OR for the association with anx-
ety in young adulthood was 1.18 (95% CI: 0.84, 1.67). In the cur-
ent study, similar associations were observed among HIV-positive het-
























































































































rosexual men and women. It is possible that these relationships may
perate in the opposite direction such that depression/anxiety leads to
ecreational drug use, perhaps as a form of self-medication/escape from
ymptoms. Experiencing an HIV diagnosis and living with HIV may, for
ome people, encompass high levels of comorbid physical and psycho-
ogical distress ( Lampe et al., 2013 ). Cannabis has a long history of be-
ng used for therapeutic purposes in people living with HIV ( Costiniuk &
enabian, 2019 ), and there is some evidence from North American stud-
es that medicinal cannabis use remains common in the modern ART era
or managing comorbidities and alleviating symptoms of anxiety and de-
ression ( Belle-Isle & Hathaway, 2007 ; Harris et al., 2014 ). This may to
ome extent explain the strong associations observed between drug use
nd poor mental health symptoms among heterosexual men and women
iving with HIV in the current study, among whom the burden of depres-
ion and anxiety was greater. 
trengths and limitations 
Strengths of this study include the presentation of drug-specific
revalence estimates and their correlates among both HIV-negative het-
rosexuals and heterosexuals living with HIV in England, over a similar
ime period. The AURAH and ASTRA studies asked about recent recre-
tional drug use, with a recall period of three months. Infrequent drug
se might not be captured in these studies. However, the psychoactive
ffects of drug use may be immediate and short-lived. Investigating as-
ociations of recent recreational drug use with recent sexual behavior
also in the past three months) in this analysis might provide more ac-
urate estimates of this relationship. 
In terms of limitations, the cross-sectional methodology used in this
tudy prohibits any inferences regarding causality. This study is im-
ortant in the context of HIV-negative sexual health clinic attenders
ut these findings cannot necessarily be generalized to all heterosex-
al men and women in England, given the potentially differing behav-
oral profiles of these populations. The studies did not collect informa-
ion specifically on sexualized drug use or on personality traits related
o sensation-seeking/sexual compulsivity, childhood sexual abuse, and
ntimate partner violence, all of which may be important in the con-
ext of both recreational drug use and sexual risk behavior. Some anal-
ses may have lacked power among male participants. Social desirabil-
ty bias in the form of underreporting of drug use and CLS, particularly
mong HIV-positive participants, may have also affected these analyses,
lthough all questionnaires were self-administered. Patterns of recre-
tional drug use may have changed since the ASTRA and AURAH stud-
es were conducted. Finally, the prevalence of pre-exposure prophylaxis
PrEP) use has likely increased substantially since the time of the AU-
AH study. Future studies will need to account for PrEP use in CLS
easures and investigate whether recreational drug use is associated
ith non-adherence to PrEP. It is also crucial to note that HIV-positive
eople with an undetectable viral load cannot transmit HIV ( Rodger
t al., 2019 ), but CLS may still confer risk of STI transmission and
cquisition. 
onclusions 
The prevalence of use of drugs associated with chemsex within gay
ommunities was very low among HIV-negative and HIV-positive het-
rosexual men and women in the AURAH and ASTRA studies in England.
owever, findings indicate that health care providers need to be aware
f the relatively high prevalence of cannabis, cocaine, and MDMA use
mong heterosexual men and women attending sexual health and HIV
linics, and the link with sexual activity and poor mental health symp-
oms. For HIV-negative women in particular, drug use may be a strong
arker of sexual risk behavior. Although the prevalence of recreational
rug use may be lower among heterosexual people living with HIV, spe-
ial care should be afforded to those who do use drugs, in order to treat
ny possible underlying psychological/physical distress. 12 unding 
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